Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03162302
Other study ID # 17-000276
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 24, 2017
Est. completion date May 3, 2021

Study information

Verified date April 2022
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this study is to develop and evaluate novel magnetic resonance imaging (MRI) protocols for studying the structure and function of the human body using 1.5 Tesla and 3.0 Tesla MRI scanners with or without the use of an MRI contrast agent.


Description:

This study will include on-going technical development work for the non-invasive diagnosis of liver fat or iron accumulation and other abnormalities. MRI is a non-invasive imaging technique with no known side effects. The study will utilize imaging equipment that is used routinely in numerous hospitals and clinics around the world. The project seeks to address optimization of the imaging methodology at 1.5 Tesla and 3.0 Tesla in the liver and abdomen in order to improve clinical evaluation and care of future patients. Non contrast MRI studies will be performed in normal healthy subjects. In addition, the study will include subjects with confirmed disease or who have suspicion for disease, and are undergoing contrast or non-contrast MR imaging as part of their standard of care. Up to sixty-five (65) male or female subjects eighteen years of age and older will be studied in total (number includes healthy subjects and non-healthy subjects). Currently, clinical MRI exams are of adequate spatial and temporal resolution, sufficient quantitative accuracy, and acceptable exam duration, but improvements in each of these areas would benefit the care of future patients. For example, improvements in spatial and temporal resolution may confer greater conspicuity of disease and shortening the exam duration can be expected to improve patient acceptance and minimize motion artifacts. The study explores innovative ideas about ways to improve MRI exams to have impact in all three of these areas. Current MRI techniques for fat and iron quantification in the liver and abdomen are challenged by respiratory and organ motion. As a result, imaging parameters (coverage, resolution, etc) and TE (echo time) selection for fat/iron quantification are compromised to accommodate a short breath-held 2D or 3D scan, which can still be affected by motion artifacts and even unachievable for patients with limited breath-holding capability. Therefore, the study aims to achieve robust free-breathing fat/iron quantification in the liver and abdomen using innovative MRI techniques and algorithms.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date May 3, 2021
Est. primary completion date May 3, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Healthy Volunteers: - Healthy subjects 18 years or older 2. Clinical Patients: - Patients who are 18 years or older and who are scheduled for a routine clinically indicated MRI exam at University of California Los Angeles Exclusion Criteria: 1. Healthy Volunteers: - Age less than 18 years - Subject with the following devices/implants/conditions will be excluded: 1. cardiac pacemakers 2. defibrillators 3. cochlear implants 4. intraocular metallic foreign bodies 5. intracranial aneurysm clips 6. claustrophobia - Subjects will be excluded if they have a history of severe renal disease (Creatinine level >2.5 mg/dl or Glomerular Filtration Rate <15 ml/minute/1.73m2 ) or allergy to MRI contrast agents ("dyes"). Healthy volunteers will not be studied with these agents. - Pregnant subjects will not be enrolled. Although there is no data to suggest that MRI is harmful to the fetus, this study is limited to non-pregnant subjects. 2. Clinical Patients: - Age less than 18 years - Subject with the following devices/implants/conditions will be excluded: 1. cardiac pacemakers 2. defibrillators 3. cochlear implants 4. intraocular metallic foreign bodies 5. intracranial aneurysm clips 6. claustrophobia - Subjects will be excluded if they have a history of severe renal disease (Creatinine level >2.5 mg/dl or Glomerular Filtration Rate <15 ml/minute/1.73m2 ) or allergy to MRI contrast agents ("dyes"). - Pregnant subjects will not be enrolled. Although there is no data to suggest that MRI is harmful to the fetus, this application is limited to non-pregnant subjects.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.

Locations

Country Name City State
United States University of California Los Angeles Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of California, Los Angeles Siemens Corporation, Corporate Technology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proton Density Fat Fraction (0 to 100%) in the liver of each subject MRI based measurement of liver fat content using proton density fat fraction 2 years
Primary Transverse Magnetization Relaxation Rate R2* (1/sec) in the liver of each subject MRI based measurement of R2* is associated with underlying liver iron content 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05255042 - Tissue Models for Liver Disease
Completed NCT04473482 - Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Recruiting NCT03773887 - Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease N/A
Recruiting NCT00345930 - DILIN - Prospective Study
Completed NCT00148031 - Improving Hepatitis C Treatment in Injection Drug Users Phase 4
Terminated NCT00031135 - Total Parenteral Nutrition-Associated Liver Disease Phase 2
Completed NCT00005305 - Hepatitis Delta Infections in Hemophiliacs N/A
Completed NCT00005304 - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed NCT00222664 - Qidong Hepatitis B Intervention Study Phase 4
Recruiting NCT06195917 - Robotic-assisted Percutaneous Transhepatic Puncture N/A
Recruiting NCT04551742 - Social & Contextual Impact on Children Undergoing Liver Transplantation
Completed NCT04782050 - Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation N/A
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Recruiting NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC Phase 2
Recruiting NCT05499585 - Treating Pediatric NAFLD With Nutrition N/A
Terminated NCT03396705 - Liver Regeneration
Completed NCT04341012 - Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
Recruiting NCT05733832 - A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease N/A